Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Coagulation factor XI

Coagulation factor XI

Brief Information

Name:Coagulation factor XI
Target Synonym:EC 3.4.21,EC:3.4.21.27,FXI,F11,PTA,Coagulation Factor XI,Plasma Thromboplastin Antecedent,EC 3.4.21.27,Factor XI,Coagualtion Factor XI
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FXI-H52H5 Human Human Coagulation factor XI / FXI Protein, His Tag (active enzyme)
FXI-H52H5-structure
FXI-H52H5-sds

Synonym Name

Coagulation factor XI,FXI,PTA,F11

Background

Coagulation factor XI is also known as F11, PTA and FXI. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with high molecular weight kininogen. Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.  Factor XI is converted into XIa via either the contact phase of blood coagulation or thrombin-mediated activation on the platelet surface. The resulting XIa converts factor IX into IXa, which subsequently activates factor X into Xa.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Factor XI concentrate (factor XI deficiency), CSL Behring Approved Csl Behring Llc Australia Factor XI Deficiency Csl Behring Llc 2014-07-01 Factor XI Deficiency Details
Human coagulation Factor XI (LFB) Approved Lfb Biotechnologies Hemoleven EU Factor XI Deficiency Lfb Biotechnologies Sas 1999-07-01 Factor XI Deficiency Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Factor XIa Inhibitor (Bayer) Factor XIa Inhibitor (Bayer) Phase 1 Clinical Blood Coagulation Disorders Details
SAL-0104 SAL-0104; SAL0104 Phase 1 Clinical Suzhou Genemen Biotech Co Ltd Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis Details
SKB-336 SKB-336 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Thromboembolism Details
KN060 KN-060 Phase 1 Clinical Suzhou Alphamab Co Ltd Thromboembolism Details
BMS-262084 BMS-262084 Phase 1 Clinical Bristol-Myers Squibb Company Thrombosis Details
IONIS-FXIRX FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 Phase 2 Clinical Ionis Pharmaceuticals Inc Venous Thromboembolism; Thrombosis Details
BAY-1831865 AB-012; BAY-1831865 Phase 1 Clinical Aronora Thrombosis Details
ONO-7269 ONO-7269 Phase 1 Clinical Ono Pharmaceutical Co Ltd Cerebral Infarction Details
BMS-986209 BMS-986209 Bristol-Myers Squibb Company Details
NIP-003 NIP003 Phase 1 Clinical National Institutes Of Pharmaceutical Research And Development Co Ltd Venous Thrombosis Details
SHR2285 SHR-2285 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Embolism; Venous Thromboembolism; Thrombosis Details
Fesomersen ION-957943; IONIS-FXI-LRx; BAY-2976217 Phase 1 Clinical Ionis Pharmaceuticals Inc Thromboembolism Details
Ir-CPI Ir-CPI Phase 1 Clinical Details
REGN-9933 REGN-9933 Phase 1 Clinical Regeneron Pharmaceuticals Inc Details
Milvexian BMS-986177; JNJ-70033093; JNJ-3093 Phase 1 Clinical Bristol-Myers Squibb Company Thromboembolism Details
ONO-7684 ONO-7684 Ono Pharmaceutical Co Ltd Details
BMS-962212 BMS-962212; BMS-96221202; BMS-962212-02 Bristol-Myers Squibb Company Details
Asundexian BAY-2433334 Phase 2 Clinical Bayer AG Stroke; Thromboembolism Details
EP-7041 EP-7041; HSK36273; HSK-36273; EP7041 Phase 2 Clinical Exithera Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Thrombocytopenia; Thrombosis Details
MK-2060 MK-2060 Phase 2 Clinical Merck Sharp & Dohme Corp Uremia; Kidney Failure, Chronic Details
Osocimab BAY-1213790 Phase 2 Clinical Bayer AG Thromboembolism; Uremia; Kidney Failure, Chronic Details
Xisomab 3G3 (Oregon Health & Science University) AB-022; AB-023 Phase 2 Clinical Oregon Health & Science University Solid tumours; Multiple Myeloma; Lymphoma Details
Abelacimab MAA-868; NOV-12 Phase 3 Clinical Novartis Pharma Ag Pulmonary Embolism; Venous Thromboembolism; Stroke; Atrial Fibrillation; Venous Thrombosis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message